Key Highlights

  • China SXT Pharmaceuticals (NASDAQ:SXTC) fell 13.90% to USD 3.53 in early trading on Monday, October 26, 2026, the day its 1-for-100 consolidation of Class A ordinary shares took effect at the open.
  • Before the consolidation the company had 68,677,500 shares outstanding, and it expects about 686,775 Class A shares and 2 Class B shares afterwards, with fractional shares rounded up to the next whole share.
  • The company announced a USD 12 million registered direct offering on Thursday, October 8, 2026, with an option for investors to buy up to a further USD 12 million, and warrant terms were later clarified.
  • The ticker remains SXTC on Nasdaq under a new CUSIP identifier, G2161P181, so the quote after the split is not comparable with earlier unadjusted prices.

China SXT Pharmaceuticals (NASDAQ:SXTC) trades after its consolidation

China SXT Pharmaceuticals (NASDAQ:SXTC), a Chinese maker of traditional Chinese medicine products, announced a 1-for-100 consolidation of its Class A ordinary shares on Thursday, October 22, 2026, effective at the open of trading on Monday, October 26, 2026. The shares traded at USD 3.53 in early trading, down 13.90% on a split-adjusted basis, which implies a prior close near USD 4.10, calculated from the move. Before the consolidation the quote was only a few cents, with delayed prices of USD 0.05 to USD 0.073 on October 22, 2026. The move is therefore partly an artefact of the share count change, and prices on Monday are intraday. The company has not stated its purpose in the release of Thursday, October 22, 2026.

How a Consolidation and an Offering Work Together

A consolidation, known in the United States as a reverse split, merges many old shares into one, so a 1-for-100 ratio cuts the count from 68,677,500 to about 686,775 Class A shares and multiplies the quoted price by 100. It does not change the value of a holding. China SXT Pharmaceuticals (NASDAQ:SXTC) also announced a USD 12 million registered direct offering on Thursday, October 8, 2026, in which shares and warrants are sold to selected investors, with an option for a further USD 12 million within 30 days of closing. Warrants are rights to buy shares at a set price, and exercise adds shares later. Both steps point to dilution risk, since new shares reduce the percentage owned by existing holders.

Risks and What to Watch

The main risks for China SXT Pharmaceuticals (NASDAQ:SXTC) are dilution, thin liquidity and post-split drift. After a consolidation the float, the shares available for public trading, is very small, so prices can swing widely on small volumes, and shares often fall back after the adjustment. Warrant exercises and the optional second tranche of the offering could add shares, and the company has not stated whether the step addresses a minimum bid requirement. Operating risks include regulation of traditional Chinese medicine in China. Investors should watch trading on Tuesday, October 27, 2026, the Fed decision on Wednesday, October 28, 2026, the 30-day option window that follows the offering closing, and any filing on warrant exercises or the exchange.

Where Things Stand

The answer is that the 13.90% fall to USD 3.53 comes on the first session after a 1-for-100 consolidation, so the move is split-adjusted and combines an artefact of the new share count with real dilution pressure from a USD 12 million offering and warrants. China SXT Pharmaceuticals (NASDAQ:SXTC) now has about 686,775 Class A shares. The next catalysts are trading on Tuesday, October 27, 2026, the Fed meeting on Wednesday, October 28, 2026 and the end of the offering option window. Micro-cap prices are volatile and illiquid, and this is not investment advice.